Ovarian Cancer Metastatic Recurrent
5 clinical trials · Condition
◉ Watch Ovarian Cancer Metastatic Recurrent
| Record | Firm | Date |
|---|---|---|
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (NCT07340164) | Yonsei University | 2026-02-26 |
| Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study (NCT07311577) | Jiangsu Cancer Institute & Hospital | 2026-01-01 |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (NCT07444814) | Whitehawk Therapeutics, Inc. | 2025-12-19 |
| Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression (NCT06839144) | Tel-Aviv Sourasky Medical Center | 2025-03-12 |
| Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (NCT00484432) | AGC Biologics S.p.A. | 2008-11-01 |
Track Ovarian Cancer Metastatic Recurrent automatically
Every clearance here is in the API, with alerts when new ones post.